The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst
: You've answered a couple of these questions, but a little more granularity, just how -- in terms of the COVID impact, we're not back to normal,
you're seeing an improvement, but how are you thinking about the impact relative to the guidance you have going forward?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
SEPTEMBER 30, 2021 / 12:00PM, ANGO.OQ - Q1 2022 AngioDynamics Inc Earnings Call
Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst
: And how should we think about Q2, given that you had such a robust Q1 and you're basically lifting 2022 for the Q1 results. And I think historically,
you will probably see something like 3% to 5% increase from Q1 to Q2, but I don't think that's where consensus is now. How should we think about
that.
Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst
: And then, one of the questions we've actually received lately from a lot of investors is just nursing staff shortages and especially and probably
because Wall Street is so New York-centric, but especially as some of these mandated vaccine requirements go into effect. And just curious if you
have any thoughts regarding -- what you've seen regarding if any of these mandates going in and there's some staff shortages and impact on your
business?
Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst
: And then, the last question for me is just, with the Auryon business and what you're seeing, how much of that is replacing laser atherectomy versus
mechanical atherectomy devices?
|
